First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Nature Medicine · 2025-04 · 31 (4) · 1163-1170
DOI: 10.1038/s41591-024-03450-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nature Medicine, online erschienen am 22.01.2025. Verfasst von Lin Shen und 59 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Esophagogastric Junction, Stomach Neoplasms, Adenocarcinoma, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China (National Science Foundation of China).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here. This was a randomized, double-blind, placebo-controlled phase 3 study. Eligible patients were adults with untreated, unresectable, locally advanced or metastatic G/GEJ adenocarcinoma. Patients were randomized 1:1 to receive cadonilimab (10 mg kg-1 every 3 weeks) or placebo plus chemotherapy (every 3 weeks). The primary endpoint was overall survival (OS) in the intention-to-treat population (one-sided significance level, P = 0.025). Secondary endpoints included OS in patients with a PD-L1 combined positive score ≥5, progression-free survival, objective response rate, duration of response and safety. As of 18 August 2023, 610 patients from 75 study centers were randomized to cadonilimab (n = 305) or placebo (n = 305). With a median follow-up of 18.7 months, the cadonilimab group had a significantly longer median OS (14.1 versus 11.1 months; hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.54-0.81; P < 0.001) than the placebo group. The primary endpoint was met. The median progression-free survival was 7.0 months versus 5.3 months (HR 0.53, 95% CI 0.44-0.65). The median OS in patients with a PD-L1 combined positive score ≥5 was 15.3 months versus 10.9 months (HR 0.58, 95% CI 0.41-0.82). The objective response rate was 65.2% versus 48.9% with a median duration of response of 8.8 months versus 4.4 months. Grade ≥3 treatment-related adverse events occurred in 65.9% of the cadonilimab group and 53.6% of the placebo group, and the most common were decreased platelet count, decreased neutrophil count and anemia. Most of the immune-related adverse events were grade 1 or 2. No new safety signals were observed. Cadonilimab plus chemotherapy significantly improved OS with a manageable safety profile in patients with advanced G/GEJ adenocarcinoma. ClinicalTrials.gov registration: NCT05008783 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.
- Harbin Medical University Cancer Hospital, Harbin, China.
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Gastroenterology, Shandong Cancer Hospital, Jinan, China.
- Shanxi Provincial Cancer Hospital, Taiyuan, China.
- Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Förderung
- National Natural Science Foundation of China (National Science Foundation of China)
Zitieren
APA
Shen, L., Zhang, Y., Li, Z., Zhang, X., Gao, X., Liu, B., Wang, Y., Ba, Y., Li, N., Zhang, R., Zhang, J., Chen, Y., Chen, J., Huang, M., Fu, Y., Liu, M., Liu, Z., Zhao, J., Li, W., …, & Li, X. (2025). First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nature Medicine, 31(4), 1163-1170. https://doi.org/10.1038/s41591-024-03450-4
Vancouver
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nature Medicine. 2025;31(4):1163-1170. doi:10.1038/s41591-024-03450-4
BibTeX
@article{Shen2025,
author = {Shen, Lin and Zhang, Yanqiao and Li, Ziyu and Zhang, Xiaotian and Gao, Xiangyu and Liu, Bo and Wang, Yusheng and Ba, Yi and Li, Ning and Zhang, Ruixing and Zhang, Jingdong and Chen, Ye and Chen, Jian and Huang, Mingzhu and Fu, Yang and Liu, Mulin and Liu, Zheng and Zhao, Jun and Li, Wei and Wei, Jia and Li, Changzheng and Xu, Nong and Guo, Zengqing and Cao, Bangwei and Liu, Lian and Nie, Peng and Wan, Lixin and Sheng, Lili and Liu, Zhenyang and He, Yifu and Gu, Kangsheng and Wu, Guowu and Wang, Weibo and Zhang, Futong and Qiu, Wensheng and Guo, Jun and Ying, Jieer and Pan, Hongming and Xu, Huiting and Yuan, Yuan and Bai, Yuansong and Wang, Zhenghua and Xu, Jiye and Zhao, Xuehong and Liu, Hao and Zhang, Xizhi and Dai, Wenxiang and Xu, Hongyan and Liu, Ming and Xie, Lin and Tang, Yong and Jin, Jianying and Qu, Xiujuan and Fang, Xuefeng and Huang, Mingwei and Chen, Hao and Zheng, Zhendong and Wang, Ying and Wang, Daqing and Li, Xiaoqin},
title = {First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {4},
pages = {1163--1170},
doi = {10.1038/s41591-024-03450-4}
}
EUVIMED